IL283395B2 - Arylmethylureas and substituted heteroarylmethylureas, their analogues and their uses - Google Patents

Arylmethylureas and substituted heteroarylmethylureas, their analogues and their uses

Info

Publication number
IL283395B2
IL283395B2 IL283395A IL28339521A IL283395B2 IL 283395 B2 IL283395 B2 IL 283395B2 IL 283395 A IL283395 A IL 283395A IL 28339521 A IL28339521 A IL 28339521A IL 283395 B2 IL283395 B2 IL 283395B2
Authority
IL
Israel
Prior art keywords
ethyl
fluorophenyl
oxo
dihydroisoquinolin
chloro
Prior art date
Application number
IL283395A
Other languages
English (en)
Hebrew (he)
Other versions
IL283395B1 (en
IL283395A (en
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of IL283395A publication Critical patent/IL283395A/en
Publication of IL283395B1 publication Critical patent/IL283395B1/en
Publication of IL283395B2 publication Critical patent/IL283395B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/28—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N<
    • A01N47/30—Derivatives containing the group >N—CO—N aryl or >N—CS—N—aryl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL283395A 2018-12-12 2019-12-11 Arylmethylureas and substituted heteroarylmethylureas, their analogues and their uses IL283395B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778471P 2018-12-12 2018-12-12
US201962896237P 2019-09-05 2019-09-05
PCT/US2019/065756 WO2020123674A1 (en) 2018-12-12 2019-12-11 Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same

Publications (3)

Publication Number Publication Date
IL283395A IL283395A (en) 2021-07-29
IL283395B1 IL283395B1 (en) 2024-03-01
IL283395B2 true IL283395B2 (en) 2024-07-01

Family

ID=71076715

Family Applications (2)

Application Number Title Priority Date Filing Date
IL283395A IL283395B2 (en) 2018-12-12 2019-12-11 Arylmethylureas and substituted heteroarylmethylureas, their analogues and their uses
IL310611A IL310611A (en) 2018-12-12 2019-12-11 Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL310611A IL310611A (en) 2018-12-12 2019-12-11 Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same

Country Status (15)

Country Link
US (1) US20230045421A1 (https=)
EP (1) EP3893645B1 (https=)
JP (2) JP7410950B2 (https=)
KR (1) KR20210102942A (https=)
CN (1) CN113923988B (https=)
AU (2) AU2019397481B2 (https=)
BR (1) BR112021011381A2 (https=)
CA (1) CA3122568A1 (https=)
IL (2) IL283395B2 (https=)
MX (1) MX2021006997A (https=)
PH (1) PH12021551369A1 (https=)
SG (1) SG11202105272YA (https=)
TW (2) TW202415643A (https=)
WO (1) WO2020123674A1 (https=)
ZA (1) ZA202103683B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202214585A (zh) * 2020-06-08 2022-04-16 加拿大商愛彼特生物製藥公司 經取代之異喹啉基甲基醯胺類、其類似物及使用其之方法
TW202214572A (zh) * 2020-06-17 2022-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲、其類似物及晶形的合成及其使用方法
JP6971444B1 (ja) * 2021-02-26 2021-11-24 千住金属工業株式会社 フラックス
KR102783985B1 (ko) * 2021-10-12 2025-03-21 주식회사 메타이뮨 신규한 캡시드 조립 저해제
KR20230051940A (ko) * 2021-10-12 2023-04-19 (주)에이엠사이언스 신규한 캡시드 조립 저해제
IL318082A (en) * 2022-08-01 2025-02-01 Valo Health Inc Process for preparing 1-(2H)-ISOQUINOLINONE-type materials modified at position 6, and intermediates obtained in the process
TW202517614A (zh) 2023-07-12 2025-05-01 瑞士商先正達農作物保護股份公司 ２－（三氟甲基）吡啶－４－胺的合成

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4623652A (en) * 1981-11-12 1986-11-18 American Hospital Supply Corporation Esters of thiadiazole oxypropanolaine derivatives and pharmaceutical uses
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
AU7440691A (en) * 1990-03-12 1991-10-10 Yamanouchi Pharmaceutical Co., Ltd. Monourea derivative and its salt
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
EP0634402A1 (en) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
US6211373B1 (en) * 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
AU5923998A (en) 1997-01-31 1998-08-25 Avid Therapeutics Inc. 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US8609663B2 (en) * 2009-11-18 2013-12-17 University Of Massachusetts Compounds for modulating TLR2
RU2012146246A (ru) * 2010-03-31 2014-05-10 Актелион Фармасьютиклз Лтд Антибактериальные производные изохинолин-3-илмочевины
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8921381B2 (en) 2010-10-04 2014-12-30 Baruch S. Blumberg Institute Inhibitors of secretion of hepatitis B virus antigens
EA024762B9 (ru) 2011-06-30 2017-04-28 Эрроухэд Рисерч Корпорейшн Композиции и способы ингибирования экспрессии генов вируса гепатита в
JP5977347B2 (ja) 2011-07-01 2016-08-24 バルーク エス．ブルームバーグ インスティテュート Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
BR112014015197A8 (pt) 2011-12-21 2017-06-13 Novira Therapeutics Inc agentes antivirais de hepatite b
BR112014021498A2 (pt) 2012-02-29 2017-07-18 Institute For Hepatitis And Virus Res composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ES2575398T3 (es) 2012-03-31 2016-06-28 F. Hoffmann-La Roche Ag 4-Metil-dihidropirimidinas novedosas para el tratamiento y la profilaxis de la infección por el virus de la hepatitis B
EA026957B1 (ru) 2012-08-28 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
KR102271574B1 (ko) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
WO2014089296A2 (en) 2012-12-06 2014-06-12 Institute For Hepatitis And Virus Research Functionalized benzamide derivatives as antiviral agents against hbv infection
BR112015015584A2 (pt) 2012-12-27 2017-12-12 Baruch S Blumberg Inst novos agentes antivirais contra infecção por hbv
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
DK2997019T3 (en) 2013-05-17 2018-12-03 Janssen Sciences Ireland Uc SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
TWI733288B (zh) 2013-05-17 2021-07-11 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
HRP20180791T1 (hr) 2013-07-25 2018-09-07 Janssen Sciences Ireland Uc Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015073774A1 (en) 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EA201691261A1 (ru) 2014-01-30 2016-11-30 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
TW201620893A (zh) 2014-02-06 2016-06-16 健生科學愛爾蘭無限公司 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
AU2015226206B2 (en) 2014-03-07 2017-03-16 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
ES2748029T3 (es) 2014-03-13 2020-03-12 Univ Indiana Res & Tech Corp Moduladores alostéricos de proteína núcleo de hepatitis B
KR20160148715A (ko) 2014-05-13 2016-12-26 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
CN106459061B (zh) 2014-05-30 2020-01-21 齐鲁制药有限公司 作为hbv抑制剂的二氢嘧啶并环衍生物
BR112017002970B1 (pt) 2014-08-14 2023-04-11 F. Hoffmann-La Roche Ag Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
CN107406378A (zh) 2014-12-02 2017-11-28 诺维拉治疗公司 用于hbv治疗的硫化烷基化合物和吡啶类反式磺酰胺化合物
CN107108610B (zh) 2014-12-30 2019-06-04 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
HK1244281B (zh) 2015-02-11 2020-02-07 F. Hoffmann-La Roche Ag 治疗和预防乙型肝炎病毒感染的2-氧代-6，7-二氢苯并[a]喹嗪-3-甲酸衍生物
EP3256461B1 (en) * 2015-02-13 2023-09-13 Azienda Ospedaliera Universitaria Senese Urea and sulfonamide derivatives as human helicase ddx3 inhibitors useful in the treatment of viral diseases
WO2016177655A1 (en) 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CN107849037B (zh) 2015-07-21 2020-04-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
WO2017015451A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017016921A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
WO2017016960A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
JP6506880B2 (ja) 2015-07-27 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
WO2017017043A1 (en) 2015-07-28 2017-02-02 F. Hoffmann-La Roche Ag Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
TWI721016B (zh) 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
WO2017064156A1 (en) 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2017102648A1 (en) 2015-12-15 2017-06-22 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a nucleos(t)ide analogue
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
WO2017108630A1 (en) 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
WO2017114812A1 (en) 2015-12-29 2017-07-06 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an interferon
US20200270265A1 (en) 2016-02-19 2020-08-27 Novartis Ag Tetracyclic pyridone compounds as antivirals
JP2019530732A (ja) 2016-08-03 2019-10-24 アライジング・インターナショナル・インコーポレイテッドＡｒｉｓｉｎｇ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｉｎｃ． 免疫モジュレータとして有用な対称または半対称化合物
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
SG11201902944TA (en) 2016-11-07 2019-05-30 Arbutus Biopharma Corp Substituted pyridinone-containing tricyclic compounds, and methods using same
EP3558970B1 (en) 2016-12-20 2021-09-01 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP3564237A4 (en) 2016-12-29 2020-06-10 Shenzhen Chipscreen Biosciences Co., Ltd. UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
TW202214574A (zh) * 2020-06-08 2022-04-16 加拿大商愛彼特生物製藥公司 經取代之(呔-1-基甲基)脲類、經取代之n-(呔-1-基甲基)醯胺類及其類似物

Also Published As

Publication number Publication date
CA3122568A1 (en) 2020-06-18
AU2019397481A1 (en) 2021-06-10
CN113923988B (zh) 2024-12-13
EP3893645B1 (en) 2024-04-17
BR112021011381A2 (pt) 2021-08-31
JP2022513845A (ja) 2022-02-09
SG11202105272YA (en) 2021-06-29
PH12021551369A1 (en) 2021-11-29
EP3893645A4 (en) 2022-08-03
AU2024200603A1 (en) 2024-02-22
WO2020123674A1 (en) 2020-06-18
IL310611A (en) 2024-04-01
IL283395B1 (en) 2024-03-01
EP3893645A1 (en) 2021-10-20
AU2019397481B2 (en) 2023-12-14
ZA202103683B (en) 2024-09-25
CN113923988A (zh) 2022-01-11
IL283395A (en) 2021-07-29
TW202035359A (zh) 2020-10-01
JP7410950B2 (ja) 2024-01-10
TW202415643A (zh) 2024-04-16
KR20210102942A (ko) 2021-08-20
US20230045421A1 (en) 2023-02-09
TWI827760B (zh) 2024-01-01
JP2024038037A (ja) 2024-03-19
MX2021006997A (es) 2021-11-12

Similar Documents

Publication Publication Date Title
IL283395B2 (en) Arylmethylureas and substituted heteroarylmethylureas, their analogues and their uses
JP2022513845A5 (https=)
RU2326869C2 (ru) Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4), способ их получения, фармацевтическая композиция и способ лечения
JP2021503458A5 (https=)
US8642602B2 (en) Method of inhibiting fibrogenesis and treating fibrotic disease
JP2013544893A5 (https=)
TWI579284B (zh) 咪唑并吡咯啶酮化合物
RU2413727C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
JP2022551422A5 (https=)
JP2021516232A5 (https=)
AR048346A1 (es) Piridonas sustituidas como inhibidores de poli(adp-ribosa)-polimerasa (parp), composiciones farmaceuticas que las contienen y el uso de las mismas para el tratamiento de trastornos cardiovasculares y del sistema nervioso central.
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
RU2008145225A (ru) Соединения индазола и способы ингибирования cd7
RU2010126050A (ru) Антибактериальные нуклеозидные соединения
RU2012139828A (ru) Производные пиразолопиперидина в качестве ингибиторов nadph-оксидазы
JP2007517807A5 (https=)
JP2022548602A5 (https=)
JP2018522861A5 (https=)
RU2009129119A (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
RU2004130488A (ru) Пиримидиновые производные
JP2017530199A5 (https=)
CA2440228A1 (en) Inhibitors of cyclin dependent kinases as anti-cancer agent
JP2019507114A5 (https=)
RU2015144385A (ru) Ациклические цианоэтилпиразолопиридоны в качестве ингибиторов янус-киназы
RU2008122405A (ru) Замещенные производные циннолина в качестве модуляторов гамма-рецепторов и способ их синтеза